Breaking News Instant updates and real-time market news.

PCLN

Priceline

$1,739.71

5.26 (0.30%)

, CMI

Cummins

$165.08

-2.325 (-1.39%)

10:17
12/01/17
12/01
10:17
12/01/17
10:17

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Priceline (PCLN) downgraded to Hold from Buy at Argus with analyst John Staszak downgraded Priceline (PCLN) saying shares are fairly valued around the current price level of $1,740 as the stock trades near the high-end of its five-year PE range. 2. Cummins (CMI) downgraded to Neutral from Buy at Goldman Sachs with analyst Jerry Revich saying to position for the next leg of the Machinery recovery, he prefers exposure to agriculture over trucks. 3. VMware (VMW) was downgraded to Hold from Buy at Gabelli and Drexel Hamilton. 4. Barnes & Noble (BKS) downgraded to Hold from Buy at Craig-Hallum with Alex Fuhrman citing the company's second quarter revenue miss. 5. Regeneron (REGN) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying she believes the competitive threat from Novartis' (NVS) vision-loss drug RTH258 is being underappreciated by the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

PCLN

Priceline

$1,739.71

5.26 (0.30%)

CMI

Cummins

$165.08

-2.325 (-1.39%)

VMW

VMware

$123.56

3.45 (2.87%)

BKS

Barnes & Noble

$6.63

-0.275 (-3.99%)

REGN

Regeneron

$361.86

3.23 (0.90%)

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 09

    Dec

  • 11

    Dec

  • 17

    Jan

PCLN Priceline
$1,739.71

5.26 (0.30%)

12/01/17
ARGS
12/01/17
DOWNGRADE
ARGS
Hold
Priceline downgraded to Hold at Argus on weak Q4 guidance and valuation
As reported earlier, Argus analyst John Staszak downgraded Priceline to Hold from Buy, saying shares are fairly valued around the current price level of $1,740 as the stock trades near the high-end of its five-year PE range. The analyst says the valuation is appropriate based on the company's near-term prospects, pointing to the company's latest Q4 forecast of 8%-13% bookings growth, which is below the prior view of 17%. Staszak also notes that Priceline has seen "significantly higher compensation costs" in Q3 and may face even higher expenses as it expands TV advertising for Booking.com to 18 more countries.
12/01/17
ARGS
12/01/17
DOWNGRADE
ARGS
Hold
Priceline downgraded to Hold from Buy at Argus
11/07/17
SUSQ
11/07/17
NO CHANGE
SUSQ
TripAdvisor price target lowered to $28 from $32 at Susquehanna
Susquehanna analyst Shyam Patil believes Priceline's (PCLN) "downstream impact" will continue to weight on TripAdvisor (TRIP), and lowered his price target on TripAdvisor to $28 from $32. Patil, who also noted that TripAdvisor's third quarter revenue missed the firm's expectations, maintained a Neutral rating on TripAdvisor shares.
11/07/17
11/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Priceline (PCLN) downgraded to Neutral from Buy at Guggenheim. 2. Exxon Mobil (XOM) downgraded to Reduce from Hold at HSBC with analyst Gordon Gray saying he compares Exxon's valuation to Buy rated Shell's (RDS.A) saying it is a third higher, yet Shell generated $7B more underlying cash flow in the past 12 months, and he thinks Exxon's capex will rise by much more in 2018 in comparison. 3. Teva (TEVA) downgraded to Reduce from Hold at HSBC with analyst Steve McGarry saying the balance sheet is "over-stretched." 4. Cabot Oil & Gas (COG) downgraded to Hold from Buy at Drexel Hamilton with analyst Bob Christensen citing the temporary stay issued on the Atlantic Sunrise pipeline. 5. SMIC (SMI) downgraded to Underperform from Neutral at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CMI Cummins
$165.08

-2.325 (-1.39%)

11/21/17
JPMS
11/21/17
NO CHANGE
JPMS
Class 8 retail truck sales rose 28% in October, says JPMorgan
JPMorgan analyst Ann Duignan notes that according to ACT Research, Class 8 retail truck sales were 23,684 units in October, up 28% year-over-year but down 4% year-to-date, while net orders were 36,033 units, up 159% year-over-year and up 55% year-to-date. Truck demand has the largest incremental impact on Navistar (NAV), Paccar (PCAR), Cummins (CMI), Allison Transmission (ALSN) and Eaton (ETN), Duignan tells investors in a research note. She points out that the truck and truck components group has outperformed year-to-date, but underperformed more recently on Tesla's (TSLA) Class 8 electric semi announcement.
11/30/17
GSCO
11/30/17
DOWNGRADE
GSCO
Neutral
Goldman, preferring ag over truck, downgrades Cummins to Neutral
Goldman Sachs analyst Jerry Revich downgraded Cummins (CMI) to Neutral and lowered his price target for the shares to $180 from $192. The engine designer closed the trading day up 2% to $167.40. To position for the next leg of the Machinery recovery, Revich prefers exposure to agriculture over trucks. The analyst coupled the downgrade with an upgrade of Agco (AGCO) to Conviction Buy from Neutral.
11/30/17
GSCO
11/30/17
UPGRADE
Target $90
GSCO
Conviction Buy
Agco upgraded to Conviction Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Jerry Revich upgraded Agco (AGCO) to Buy and added the shares to his firm's Conviction List. The analyst raised his price target for the stock to $90 from $77. To position for the next leg of the Machinery recovery, Revich prefers exposure to agriculture over trucks. The analyst also downgraded Cummins (CMI) to Neutral.
11/30/17
GSCO
11/30/17
DOWNGRADE
GSCO
Neutral
Cummins downgraded to Neutral from Buy at Goldman Sachs
VMW VMware
$123.56

3.45 (2.87%)

12/01/17
GABE
12/01/17
DOWNGRADE
GABE
Hold
VMware downgraded to Hold on valuation at Gabelli
Gabelli analyst Hendi Susanto downgraded VMWare to Hold from Buy citing valuation.
12/01/17
MAXM
12/01/17
NO CHANGE
Target $123
MAXM
Hold
VMware price target raised to $123 from $113 at Maxim
Maxim analyst Nehal Chokshi raised his price target on VMware (VMW) to $123 from $113 after Q3 earnings beat, citing 11% bookings growth in computing relative to 10% in the prior quarter. Chokshi also notes an above-consensus billings growth of 21%, driven in part by acceleration in ELA bookings growth of 54%. The analyst keeps his Hold rating on VMware, adding that while near-term outlook for the company may be more favorable, in the longer term, Microsoft's (MSFT) dominance in the Software Defined Datacenter market may put more pressure on VMware's compute business.
12/01/17
OPCO
12/01/17
NO CHANGE
Target $135
OPCO
Outperform
VMware price target raised to $135 from $120 at Oppenheimer
Oppenheimer analyst Ittai Kidron raised his price target for VMware to $135 citing last night's "solid" Q3 results. The analyst is bullish on the company's hybrid cloud strategy and keeps an Outperform rating on the shares.
12/01/17
12/01/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. VMware (VMW) upgraded to Outperform from Market Perform at BMO Capital with analyst Keith Bachman saying the company is benefiting from improved on-premise spending trends, increasing his projections for the overall fiscal 2019 computing spend to grow 3% versus prior forecast of 1%-2% decline. 2. Tiffany (TIF) upgraded to Overweight from Sector Weight at KeyBanc with analyst Edward Yruma saying he believes the positive 1% Americas comp in third quarter points to the early stages of a more broad-based sales recovery. 3. Mellanox (MLNX) upgraded to Buy from Neutral at Longbow with analyst Mike Burton saying he believes activist Starboard's involvement could lead to the company being acquired in whole or in pieces, and a reduction in OPEX levels more consistent with peers. 4. Agco (AGCO) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Jerry Revich saying to position for the next leg of the Machinery recovery, he prefers exposure to agriculture over trucks. 5. Vantiv (VNTV) upgraded to Outperform from Neutral at Wedbush with analyst Moshe Katri saying its Worldpay acquisition provides exposure to the U.K. and APAC, which are high-growth, potentially more profitable regions, while also drastically reducing its national merchants exposure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BKS Barnes & Noble
$6.63

-0.275 (-3.99%)

12/01/17
12/01/17
DOWNGRADE
Target $8

Hold
Barnes & Noble downgraded to Hold following revenue miss at Craig-Hallum
As previously reported, Craig-Hallum analyst Alex Fuhrman downgraded Barnes & Noble to Hold from Buy after the company's Q2 revenue missed expectations, saying that its reiterated 2018 EBITDA guidance is now more dependent on a second half improvement and cost cuts. The analyst, who thinks weak top-line growth is likely to continue for the foreseeable future, cut his price target on B&N shares to $8 from $15.
12/01/17
CHLM
12/01/17
DOWNGRADE
CHLM
Hold
Barnes & Noble downgraded to Hold from Buy at Craig-Hallum
REGN Regeneron
$361.86

3.23 (0.90%)

11/28/17
BOFA
11/28/17
NO CHANGE
BOFA
Equity Residential, Regeneron removed from US 1 List at BofA/Merrill
11/28/17
BMOC
11/28/17
NO CHANGE
Target $444
BMOC
Market Perform
Regeneron price target lowered to $444 from $479 at BMO Capital
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron to $444, saying the Phase 2 trial failure of Eylea injection with Ang2 in AMD and DME "eliminates a potential growth source". The analyst notes that while the expectations for Ang2 were low, the setback is another example of long-term risks to Regeneron's core business. Luchini keeps his Market Perform rating, saying investors' focus now shifts to Praluent ODYSSEY outcomes data in early 2018, PANORAMA Phase III data of Eylea in diabetic retinopathy in the first half of next year, and updated Phase II data for REGN2810 in CSCC expected in the current quarter to be followed by potential filing in Q1 and proof-of-concept Phase I data for REGN3500.
12/01/17
SBSH
12/01/17
DOWNGRADE
Target $380
SBSH
Neutral
Regeneron downgraded to Neutral from Buy at Citi
Citi analyst Robyn Karnauskas downgraded Regeneron Pharmaceuticals (REGN) to Neutral and cut her price target for the shares to $380 from $480. The biotechnology company closed yesterday up 1% to $361.86. The analyst believes the competitive threat from Novartis' (NVS) vision-loss drug RTH258 is being underappreciated by the market. It is hard to believe that RTH258 would not have a price impact, at minimum, on Regeneron's Eylea, Karnauskas tells investors in a research note. The analyst points out that her dermatologist survey came back bullish for Regeneron's Dupixent. While she expects the drug to beat expectations for 2018, the analyst feels this won't be enough to offset the overhang on shares from Eylea competition.
11/16/17
EVER
11/16/17
NO CHANGE
Target $445
EVER
Outperform
Regeneron price target lowered to $445 from $605 at Evercore ISI
Evercore ISI lowered its price target for Regeneron (REGN) to $445 from $605 given meaningful competitive threat to Eylea. For every dollar of U.S. Eylea sales lost to competition, Regeneron has to make up for it with two times as much revenue from the Sanofi (SNY) JV, it adds. The firm has an Outperform rating on Regeneron's shares.

TODAY'S FREE FLY STORIES

CSX

CSX

$52.93

-4.38 (-7.64%)

15:18
12/16/17
12/16
15:18
12/16/17
15:18
Hot Stocks
CSX announces death of CEO E. Hunter Harrison »

CSX issued the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

CBOE Holdings

$126.37

0.31 (0.25%)

11:22
12/16/17
12/16
11:22
12/16/17
11:22
Periodicals
CBOE should not be treated as 'set and forget,' Barron's says »

Bitcoin futures have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

11:17
12/16/17
12/16
11:17
12/16/17
11:17
Periodicals
Disney/Fox 'a murky web of deals within deals,' Barron's says »

Walt Disney's (DIS)…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALK

Alaska Air

$70.83

1.44 (2.08%)

10:53
12/16/17
12/16
10:53
12/16/17
10:53
Periodicals
Alaska air should bounce back in 2018, Barron's says »

While shares of Alaska…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$46.37

1.16 (2.57%)

10:42
12/16/17
12/16
10:42
12/16/17
10:42
Periodicals
Spark Therapeutics selloff may be overdone, Barron's says »

Spark Therapeutics shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jan

AAPL

Apple

$173.97

1.75 (1.02%)

10:29
12/16/17
12/16
10:29
12/16/17
10:29
Periodicals
New Apple iPhone features also bring software bugs, Barron's says »

While each new Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$190.12

0.56 (0.30%)

, DIS

Disney

$111.27

0.7 (0.63%)

10:19
12/16/17
12/16
10:19
12/16/17
10:19
Periodicals
More consolidation to come after Disney/Fox deal, Barron's says »

Netflix (NFLX) success…

NFLX

Netflix

$190.12

0.56 (0.30%)

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

MSGN

MSG Networks

$19.80

0.05 (0.25%)

AMCX

AMC Networks

$55.33

1.16 (2.14%)

VIAB

Viacom

$30.24

0.53 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

09:22
12/16/17
12/16
09:22
12/16/17
09:22
Periodicals
Exxon disclosure of climate-change regulation impact has risks, Barron's says »

In a filing with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$111.27

0.7 (0.63%)

, FOXA

21st Century Fox

$34.99

0.11 (0.32%)

07:58
12/16/17
12/16
07:58
12/16/17
07:58
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

T

AT&T

$38.24

0.5 (1.32%)

CHTR

Charter

$322.31

-6.37 (-1.94%)

CMCSA

Comcast

$39.71

0.59 (1.51%)

CMCSK

Comcast

VZ

Verizon

$52.67

0.33 (0.63%)

NFLX

Netflix

$190.12

0.56 (0.30%)

AMZN

Amazon.com

$1,179.14

4.88 (0.42%)

FB

Facebook

$180.18

1.79 (1.00%)

TWTR

Twitter

$22.23

-0.35 (-1.55%)

GOOG

Alphabet

$1,064.19

15.04 (1.43%)

GOOGL

Alphabet Class A

$1,072.00

14.53 (1.37%)

DFS

Discover

$74.59

0.92 (1.25%)

SYF

Synchrony

$37.19

0.2 (0.54%)

COF

Capital One

$96.31

2.25 (2.39%)

OMF

OneMain Holdings

$25.50

0.25 (0.99%)

CIT

CIT Group

$49.78

0.64 (1.30%)

SC

Santander Consumer

$17.99

-0.29 (-1.59%)

SLM

Sallie Mae

$11.17

0.18 (1.64%)

AL

Air Lease

$45.80

1.07 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 23

    Jan

  • 07

    Feb

  • 18

    Mar

  • 14

    Dec

SHOO

Steven Madden

$44.15

1.15 (2.67%)

04:55
12/16/17
12/16
04:55
12/16/17
04:55
Conference/Events
Steven Madden management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 07

    Jan

  • 08

    Jan

STLD

Steel Dynamics

$39.85

0.01 (0.03%)

18:07
12/15/17
12/15
18:07
12/15/17
18:07
Earnings
Steel Dynamics sees Q4 EPS 48c-52c, consensus 55c »

"Despite a lower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

House plans to vote…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Republicans release final tax bill proposal, CNBC reports »

Republicans have released…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$162.60

5.4 (3.44%)

17:37
12/15/17
12/15
17:37
12/15/17
17:37
Hot Stocks
McKesson awarded $400M government contract »

McKesson has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$60.94

0.11 (0.18%)

17:34
12/15/17
12/15
17:34
12/15/17
17:34
Syndicate
Breaking Syndicate news story on Ameren »

Ameren files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKAM

Akamai

$57.76

1 (1.76%)

, AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

17:33
12/15/17
12/15
17:33
12/15/17
17:33
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Akamai (AKAM), up…

AKAM

Akamai

$57.76

1 (1.76%)

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

PG

Procter & Gamble

$91.89

0.89 (0.98%)

PETX

Aratana Therapeutics

$5.73

0.15 (2.69%)

HPE

HP Enterprise

$14.41

0.17 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 13

    Dec

GRMN

Garmin

$58.36

-1.1 (-1.85%)

17:32
12/15/17
12/15
17:32
12/15/17
17:32
Recommendations
Garmin analyst commentary at Tigress Financial »

Garmin growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$322.82

5.81 (1.83%)

17:26
12/15/17
12/15
17:26
12/15/17
17:26
Hot Stocks
Lockheed Martin awarded $135.83M government contract »

Lockheed Martin is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

PG

Procter & Gamble

$91.89

0.89 (0.98%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
Peltz to join Procter & Gamble board effective March 1, 2018 »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.89

0.89 (0.98%)

, NVS

Novartis

$84.86

0.39 (0.46%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
P&G names Trian's Nelson Peltz, Novartis CEO Jimenez to board »

Procter & Gamble (PG)…

PG

Procter & Gamble

$91.89

0.89 (0.98%)

NVS

Novartis

$84.86

0.39 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 17

    May

SNSS

Sunesis

$3.36

0.16 (5.00%)

17:16
12/15/17
12/15
17:16
12/15/17
17:16
Hot Stocks
Sunesis CEO Swisher to resign, Dayton Misfeldt named interim CEO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.24

0.5 (1.32%)

, BA

Boeing

$293.94

0.06 (0.02%)

17:09
12/15/17
12/15
17:09
12/15/17
17:09
Hot Stocks
AT&T CEO Stephenson resigns from Boeing board »

According to a regulatory…

T

AT&T

$38.24

0.5 (1.32%)

BA

Boeing

$293.94

0.06 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

HPE

HP Enterprise

$14.41

0.17 (1.19%)

17:03
12/15/17
12/15
17:03
12/15/17
17:03
Syndicate
Breaking Syndicate news story on HP Enterprise »

HP Enterprise files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

FSV

FirstService

$67.87

-0.54 (-0.79%)

17:02
12/15/17
12/15
17:02
12/15/17
17:02
Hot Stocks
Breaking Hot Stocks news story on FirstService »

Jay S. Hennick reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETP

Energy Transfer Partners

$17.50

0.08 (0.46%)

17:01
12/15/17
12/15
17:01
12/15/17
17:01
Hot Stocks
Energy Transfer gets FERC approval to place Rover Pipeline's 1B into service »

Energy Transfer Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.